NRx's trial of Zyesami to continue enrolment without changes

NRx Pharmaceuticals reported that a US NIH trial analysing Zyesami to treat critical Covid-19 patients will progress to conclude enrolment.

Related Keywords

United Kingdom , Brazil , Thiago Lazarino , Jonathan Javitt , European Union , National Institute Of Allergy , Drug Administration , Nrx Pharmaceuticals , Us National Institutes Of Health , Prevention Data Safety , Monitoring Board , National Institute , Infectious Diseases , New Drug Application , Gilead Science Veklury , Data Safety , Serious Adverse Events , Emergency Use Authorization , Preference Management Solution , Regulatory Consultation ,